Clinical Trial Update: Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration [Phase 3]

View source ↗

Summary

A Phase 3 trial update assessing the safety of brolucizumab 6 mg in a prefilled syringe for neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Brolucizumab (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age Related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2020-08-03